Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
31 results about "PINK1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
PTEN-induced kinase 1 (PINK1) is a mitochondrial serine/threonine-protein kinase encoded by the PINK1 gene. It is thought to protect cells from stress-induced mitochondrial dysfunction. PINK1 activity causes the parkin protein to bind to depolarized mitochondria to induce autophagy of those mitochondria. PINK1 is processed by healthy mitochondria and released to trigger neuron differentiation. Mutations in this gene cause one form of autosomal recessive early-onset Parkinson's disease.
Compositions and methods for treatment of neurogenerative diseases
Medical compositions and methods of treating or preventing neurodegeneration in a human suffering from or that is at risk of or susceptible to neurodegeneration or cellular dysfunction associated with expression or impaired cellular function of a neuronal protein encoded by one or more genes that code for alpha-synuclein (SNCA), Parkin RBR E3 ubiquitin protein ligase, (PARK2), Leucine-rich repeat kinase 2 (LRRK2), PTEN-induced putative kinase / (PINK1), Daisuke-Junko 1, (DJ-1) and ATPase type 13A2 (ATP13A2), are disclosed. Methods of treatment for these disorders is also provided, comprising administering a vector into a cell, wherein the vector facilitates expression of a molecular component that alters one of the aforementioned genes in the cell or expression of the gene in the cell, the gene being implicated in an etiology of the neurological deficit.
Owner:FLYNN ALEXANDER C
Parkinson's disease gene diagnosis kit
ActiveCN104928373AGuaranteed speedGuaranteed accuracyMicrobiological testing/measurementDisease riskDisease injury
The invention discloses a Parkinson's disease gene diagnosis kit which comprises 11 pathogenic genes of the Parkinson's disease namely SNCA,Parkin,Pink1,UCHL-1,DJ-1,ATP13A2,GIGYF2,HTRA2,FBX07,Vps35 and MAPT. A detection method comprises the following steps: designing and synthesizing specific primers of all genes, collecting specimens of individuals to be detected, sequencing specific DNA fragments obtained by all genes through a RT-PCR technology, comparing the gene sequence with a normal gene sequence, and analyzing whether deleterious mutations exit or not to evaluate disease risks of the individuals. By adopting the Parkinson's disease gene diagnosis kit disclosed by the invention, different deleterious mutations of a pathogenic gene protein coding region (CDS) can be detected at a time, the method is simple, convenient and rapid, the specificity is good, the sensitivity is high and the Parkinson's disease gene diagnosis kit can be used for pathogenic gene screening and early diagnosis of the Parkinson's disease.
Owner:江苏雄鸣医药科技有限公司
Diagnosis chip of recessive pathogenic genetic genes of Parkinson disease
ActiveCN103667500AReliable resultsImprove early diagnosis rateNucleotide librariesMicrobiological testing/measurementGenetic diagnosisGenomic clone
A diagnosis chip of recessive pathogenic genetic genes of a Parkinson disease has 96 mutational site sequences, namely 23 Parkin, 19 PINK1, 6 DJ-1, 14 ATP13A2, 25 PLA2G6 and 9 FBXO7. The chip comprises the following test steps of: fabricating an SUD plate, resuspending the SUD plate, fabricating an ASE plate, adding MEL, performing preliminary work on PCR (Polymerase Chain Reaction), combining PCR products, preparing a pre-chip sample, performing chip hybridization, cleaning and scanning the chip, and reading and analyzing data. The diagnosis chip of the recessive pathogenic genetic genes of the Parkinson disease is low in cost, and can screen the recessive pathogenic genetic genes of the Parkinson disease conveniently and rapidly.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.
Owner:MITOKININ INC +1
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
ActiveUS10723737B2Increase activity levelNervous disorderOrganic chemistryPharmacologyCardiomyopathy
Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.
Owner:RGT UNIV OF CALIFORNIA +1
Non-therapeutic-purpose gene editing method based on PINK1 and PARK7 through injection of virus into specific brain regions of animals
PendingCN111304252AAvoid genetic differencesIncreased mortalityHydrolasesTransferasesDisease phenotypeDisease
The invention discloses a non-therapeutic-purpose gene editing method based on PINK1 and PARK7 through injection of a virus into specific brain regions of animals. The virus is directly injected intothe specific brain regions of non-human primates by using a brain stereotaxic injection pump, wherein the injection volume is 1 [mu]L of the injected virus per 1 m<3>, and the titer of the injected virus is 10*10<13>vg / mL. Through the method, gene editing is performed directly on the specific brain regions of the non-human primates, and transgenic monkey models with disease phenotypes can be obtained in a short time, so that urgent research needs of Parkinson's syndromes (PD) at the present stage are met.
Owner:KUNMING INST OF ZOOLOGY CHINESE ACAD OF SCI
Target ZIP7 related to diagnosis, treatment, prevention and treatment of cardiovascular diseases and application of target ZIP7
InactiveCN113144199APromote autophagyAvoid it happening againPharmaceutical active ingredientsCardiovascular disorderProtein activityPharmacology
The invention discloses a target ZIP7 related to diagnosis, treatment, prevention and treatment of cardiovascular diseases and application of the target ZIP7. The application of a substance for inhibiting or silencing ZIP7 gene expression or inhibiting ZIP7 protein activity in any one of the following conditions that a medicine for increasing the concentration of zinc ions in mitochondria is prepared; a medicine for reducing the mitochondrial membrane potential is prepared; a medicine for increasing aggregation of PINK1 in mitochondria is prepared; a medicine for increasing the aggregation of Parkin in mitochondria is prepared; a medicine for inducing mitochondrial autophagy is prepared; a medicine for reducing the release level of active oxygen in myocardial tissues is prepared; a medicine for reducing the myocardial infarction risk is prepared; a medicine for treating or adjunctively treating myocardial infarction is prepared; a medicine for improving the cardiac function after myocardial infarction is prepared; a medicine for inhibiting the enlargement of the infarction area after myocardial infarction is prepared; a medicine for inhibiting ventricular negative remodeling after myocardial infarction is prepared; a medicine for reducing damage of myocardial cells and myocardial tissues in the myocardial infarction process is prepared; and a medicine for reducing the death quantity of myocardial cells in a non-infarction region after myocardial infarction is prepared.
Owner:TIANJIN MEDICAL UNIV
Method for rapidly establishing animal model of Parkinson's disease through substantia nigra gene knockout
ActiveCN108998452AAchieve specific knockoutPhenotype stableHydrolasesStable introduction of DNASide effectAnimal brain
The invention provides a method for rapidly establishing an animal model of Parkinson's disease through substantia nigra gene knockout. The invention discloses sgRNA capable of efficiently specifically knocking out PINK1 genes, and further provides a method for establishing the animal model of Parkinson's disease by virtue of targeted knockout of PINK1 genes in substantia nigra of animals. The method specifically comprises the following steps: injecting sgRNA and CRISPR nuclease into a substantia nigra part of the animal brain, and causing target fragment deletion to the PINK1 genes. Obvious typical dyskinesia symptoms of Parkinson's disease can occur within 3-4 weeks, and the dyskinesia cannot restore without drug therapy. The method directly causes neuronal death of the substantia nigrapart, does not have any side effect, has the mold establishment success rate of 90% or higher, has phenotypic stability and excellent applicability and repeatability, provides important models for screening drugs for the Parkinson's disease, performing stem cell treatment and gene defect repair treatment, researching pathogenesis of deletion of the PINK1 genes and the like, and has huge economic value and preclinical study significances.
Owner:JINAN UNIVERSITY
Gene therapy for CNS degeneration
The present disclosure relates generally to compositions and methods for treating, preventing, inhibiting, or delaying central nervous system degeneration. The disclosure relates to a recombinant genetherapy vector comprising a PARK2, PINK1, DJ-1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA gene, or functional fragment or variant thereof. The disclosure also relates to CRISPR / Cas-based gene editing systems for treating, preventing, inhibiting, or delaying central nervous system degeneration.
Owner:ROCKET PHARMA LTD
Polypeptide for preparing anti-PINK1 polyclonal antiserum and application thereof
The present invention discloses a polypeptide for preparing anti-PINK1 polyclonal antiserum and application thereof. The polypeptide of the invention is one polypeptide selected from a) and b): a) the polypeptide which is composed of amino acid sequence shown by the sequence 2 in a sequence table; and b) the polypeptide which is derived from the amino acid sequence of sequence 2 in the sequence table through substitution and / or absence and / or adding one or a plurality of amino acids. The invention also discloses the DNA molecule encoding the polypeptide. The anti-PINK1 polyclonal antiserum prepared according to the invention not only can be used for detecting Western blot, but also can be applied to immunohistochemical analysis. The anti-PINK1 polyclonal antiserum prepared according to the invention is of great significance in diagnosing and treating the disease related with PD and PINK1.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Methods for predicting cancer patient's clinical response to Anti-cancer compounds
InactiveUS20180306800A1Good disease control rateLong time to progressionMicrobiological testing/measurementAntibody ingredientsCancer cellRegimen
Methods and materials involved in assessing samples (e.g., cancer cells) for the status of PINK1-Parkin pathway biomarkers, as well as materials and methods for identifying cancer patients likely to respond to a particular cancer treatment regimen.
Owner:UNIV OF COLORADO THE REGENTS OF
New application of UFP-512
The invention provides application of UFP-512 to mitochondria protection and autophagy induction, and provides application of the UFP-512 to preparing medicines for preventing or delaying or treatingsymptoms related to and affected by mitochondria. It is shown through experimental data that the UFP-512 can effectively improve the mitochondrial membrane potential depolarization, increase the mitochondria ATP yield and reduce the cellular oxidation stress. Meanwhile, the UFP-512 can induce the autophagy of the mitochondria depending on PINK1-Parkin, thereby further clearing away the damaged mitochondria and keeping the environment in the mitochondria stable, and the application gap of diseases related to mitochondria damage and mitochondria autophagy difficulty is made up through the targeted protection effect of the UFP-512 on the mitochondria and the induction effect of the UFP-512 on the autophagy of the mitochondria.
Owner:THE FIRST PEOPLES HOSPITAL OF CHANGZHOU
Gene therapy for CNS degeneration
PendingUS20210230631A1Simple methodReduce the amount requiredNervous disorderHydrolasesNervous systemMedicine
The present disclosure relates generally to compositions and methods for treating, preventing, inhibiting, or delaying central nervous system degeneration. The disclosure relates to a recombinant gene therapy vector comprising a PARK2, PINK1, DJ-1, LRRK2, SCNA, c-Rel, ATG7, VMAT2, or GBA gene, or functional fragment or variant thereof. The disclosure also relates to CRISPR / Cas-based gene editing systems for treating, preventing, inhibiting, or delaying central nervous system degeneration.
Owner:SPACECRAFT SEVEN LLC
Applications of tartary buckwheat seed coat extract in mitochondrion activity improvement, anti-aging gene expression enhancement, and protein saccharification inhibition
PendingCN110710682AImprove mitochondrial activityBoosts anti-aging gene expressionAntinoxious agentsPlant ingredientsFagopyrum tataricumOrganic chemistry
The invention discloses a health care application of a plant extract, in particular, applications of a tartary buckwheat seed coat extract in mitochondrion activity improvement, anti-aging gene expression enhancement, and protein saccharification inhibition. The tartary buckwheat seed coat extract is prepared by extracting tartary buckwheat seed coats by water used as a solvent. The provided extract can promote the generation of energy of cells, reduce the generation of saccharified proteins, enhance the expression of multiple anti-aging genes such as CCT, PINK1, SIRT1, FOXO3, and the like, and thus can prevent hypofunction and maintain the health of individuals.
Owner:TCI CO LTD
Application of PINK1 as marker for predicting sensitivity of lung adenocarcinoma to MAPK inhibitor and recurrence of lung adenocarcinoma
PendingCN114480339AIncreased drug resistanceHigh riskMicrobiological testing/measurementTransferasesTumor recurrencePulmonary adenocarcinoma
The invention discloses application of PINK1 as a marker for predicting sensitivity of lung adenocarcinoma to an MAPK inhibitor and recurrence of lung adenocarcinoma. Through experiments, it is found that expression increase of PINK1 in tumors prompts that a lung adenocarcinoma patient has higher tumor dormancy and recurrence risks, so that dormancy and recurrence of lung adenocarcinoma can be predicted by detecting the expression level of PINK1 in the lung adenocarcinoma patient, and the blank of biomarkers for dormancy and recurrence of lung adenocarcinoma in the prior art is filled up; the expression level of PINK1 can be used as a judgment standard for lung adenocarcinoma dormancy and recurrence, and is used for developing a lung adenocarcinoma dormancy and recurrence prediction kit. Besides, for a lung adenocarcinoma patient receiving the MAPK pathway inhibitor, the increase of the expression of the PINK1 prompts that the risk of drug resistance and relapse is increased after the patient is treated, so that intervention measures can be taken in advance clinically, tumor relapse is prevented, and a new strategy and thought are provided for clinically treating the lung adenocarcinoma.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
Composition for preventing or treating autoimmune disease, comprising, as active ingredient, PINK1 protein or polynucleotide encoding same
ActiveUS9585945B2Inhibitory activityHigh activityPeptide/protein ingredientsTransferasesImmunologic disordersRegulatory T cell
Owner:THE CATHOLIC UNIV OF KOREA IND ACADEMIC COOP FOUND
Application of astragaloside IV in reduction of nanometer zinc oxide-induced neurotoxicity
InactiveCN110613748ASignificant neuroprotective effectLow toxicityOrganic active ingredientsNervous disorderAutophagic deathMass reduction
The invention discloses novel application of astragaloside IV and application of astragaloside IV in reduction of nanometer zinc oxide-induced neurotoxicity. The astragaloside IV is one of the main components of astragalus. It is shown through tests that ZnONPs-induced never cell toxicity can be prevented through induced autophagy of astragaloside IV, damaged mitochondria can be further protectedthrough PINK1 / Parkin pathway-induced mitochondrial autophagy, and the intracellular ROS content increase, reduction of MMP and calcium ion homeostasis imbalance and mitochondrial mass reduction whichare caused by ZnONPs can be reversed. It is determined that a protective effect on nanometer zinc oxide-induced neurotoxicity can be achieved by astragalus, and the protective effect of astragalosideIV on neurotoxicity is achieved; and the protective mechanism of astragaloside IV is studied through in-vitro experiments, and a foundation is laid for researches and development of new neuroprotective drugs.
Owner:SHANXI MEDICAL UNIV
Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
The present disclosure is directed to nitrogen-containing heteroaryl analogs, methods of making nitrogen-containing analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis, and / or cardiomyopathy using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Owner:MITOKININ INC
A method for quickly establishing an animal model of Parkinson's disease by knocking out the substantia nigra gene
ActiveCN108998452BAchieve specific knockoutPhenotype stableHydrolasesStable introduction of DNADiseaseSide effect
Owner:JINAN UNIVERSITY
PINK1 C-terminal domain polypeptide and methods using the same in cancer treatment
InactiveCN108290930APolypeptide with localisation/targeting motifOrganic active ingredientsDimerTyrosine
The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. ThePINK1-CTD polypeptide inhibits, prevents and / or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressingcancer therapy.
Owner:胡文聪 +2
Establishment of detection method of colon tissue PINK1/Parkin of rat dysbacteriosis diarrhea
PendingCN114480590AImprove disordered diarrheaActivate autophagyMicrobiological testing/measurementMaterial analysis by optical meansStainingRat model
The invention discloses establishment of a detection method of colon tissue PINK1 / Parkin of rat dysflora diarrhea, and the detection method comprises the following steps: preparing a rat model with dysflora diarrhea, treating the rat model with a Gegen Qinlian decoction, performing HE dyeing and RT-PAR detection, and detecting the PINK1 / Parkin in the rat model with PINK1 / Parkin. It is determined that the radix puerariae qinlian decoction can reduce the expression level of mitochondrial autophagy PINK1 / Parkin in colon tissue of a rat suffering from the dysflora diarrhea, and the radix puerariae qinlian decoction can activate mitochondrial autophagy and remove damaged mitochondria in the tissue by influencing expression of PINK1 and Parkin, so that the effect of treating the dysflora diarrhea is achieved.
Owner:贵州中医药大学
A kind of protective agent for mitochondrial function of weaned piglets
ActiveCN109619306BHigh activityIncrease contentAnimal feeding stuffAccessory food factorsBiotechnologyPost weaning
The invention discloses a protective agent for mitochondrial function of weaned piglets, which comprises the following components: 0.3-1.5 parts by weight of ellagic acid, 0.3-2 parts by weight of curcumin, 0.3-1.3 parts by weight of syringin, and 3-3 parts by weight of sodium montmorillonite 15 parts by weight. Compared with the single addition of ellagic acid, curcumin, syringin and sodium montmorillonite in the feed, the protective agent for mitochondrial function of weaned piglets of the present invention significantly improves the content of mitochondrial DNA in the intestinal tract and liver of post-weaned piglets, and the mitochondrial respiratory chain. Complex IV activity, expression of mitophagy marker proteins PINK1, Parkin, and LC3II / LC3I. Ellagic acid, curcumin, syringin, and sodium montmorillonite have significant interactions in improving intestinal and liver mitochondrial function and mitophagy levels, and have a positive synergistic combination effect. The protective agent for mitochondrial function of weaned piglets of the present invention can significantly improve the mitochondrial autophagy levels of the intestinal tract and liver after weaning through the synergistic effect of various components, and greatly improve the mitochondrial functions of the intestinal tract and liver after weaning.
Owner:ZHEJIANG UNIV
A mitophagy regulator that relieves oxidative stress in pigs
ActiveCN109673857BReduced production of reactive oxygen speciesReduce contentAccessory food factorsBiotechnologyPig liver
The invention discloses a mitophagy regulator for relieving pig oxidative stress, which comprises the following components: 6-13 parts by weight of butyrate, 1-3 parts by weight of Achyranthes knuckle polysaccharide, 5-10 parts by weight of betaine, sodium-based 30-60 parts by weight of montmorillonite. Compared with the addition of butyrate, achyranthes bidentata polysaccharide, betaine and sodium montmorillonite alone in the feed, the present invention can significantly reduce the production of reactive oxygen species in the mitochondria of the liver and intestinal tract and the content of peroxidation product malondialdehyde, and promote oxidation stress. The expression of mitophagy marker proteins PINK1, Parkin, and LC3II / LC3I in pig liver and intestine after stimulation significantly increased the content of mitochondrial DNA and the activity of mitochondrial oxidative respiratory chain complex IV in pig liver and intestine. Moreover, Na-based montmorillonite has a controlled-release effect on butyrate, Achyranthes bidentata polysaccharide, and betaine, making it easy to mix with feed, forming a uniform dispersion system, and easy to use. Through the synergistic effect of each component, the invention significantly improves the level of pig mitophagy, protects the function of mitochondria, and then significantly relieves the oxidative stress of pigs.
Owner:ZHEJIANG UNIV
Application of target drug in resisting atherosclerosis
PendingCN113476436AInhibition levelGood interventionOrganic active ingredientsPharmaceutical delivery mechanismSide effectDrug target
The invention discloses application of a target drug in resisting atherosclerosis. The application comprises the following steps of: taking a mitochondrial autophagy signal channel mediated by nobiletin PINK1 / Parkin as a drug target; and / or taking an NLRP3 inflammasome signal channel as a drug target. According to the invention, with the application of the nobiletin, the blood fat level of atherosclerosis can be significantly reduced; the plaque structure can be significantly improved; the plaque stability can be improved; the inflammatory reaction can be inhibited; the nobiletin uses the mitochondrial autophagy signal channel mediated by the PINK1 / Parkin as the drug target; and / or, the NLRP3 inflammasome signal channel is used as the drug target; the nobiletin can be used as the effective tool for stabilizing the arteriosclerosis plaque, and provides the foundation for the development of the arteriosclerosis prevention and treatment drug; and in addition, the nobiletin is derived from the natural plant, has characteristics of wide source, low toxic-side effect, and anti-atherosclerosis effect, and has great market prospects and economic values.
Owner:SOUTHERN MEDICAL UNIVERSITY
Polypeptide for preparing anti-PINK1 polyclonal antiserum and application thereof
The present invention discloses a polypeptide for preparing anti-PINK1 polyclonal antiserum and application thereof. The polypeptide of the invention is one polypeptide selected from a) and b): a) the polypeptide which is composed of amino acid sequence shown by the sequence 2 in a sequence table; and b) the polypeptide which is derived from the amino acid sequence of sequence 2 in the sequence table through substitution and / or absence and / or adding one or a plurality of amino acids. The invention also discloses the DNA molecule encoding the polypeptide. The anti-PINK1 polyclonal antiserum prepared according to the invention not only can be used for detecting Western blot, but also can be applied to immunohistochemical analysis. The anti-PINK1 polyclonal antiserum prepared according to the invention is of great significance in diagnosing and treating the disease related with PD and PINK1.
Owner:CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Chimeric molecule for mediating mitochondrial targeted degradation based on autophagy mechanism and application thereof
ActiveCN111471111ARealize regulationAchieving regulation of intracellular organelles is feasible regulationNervous disorderPeptide/protein ingredientsNeuro-degenerative diseaseAmino acid
The invention discloses a chimeric molecule for mediating mitochondrial targeted degradation based on autophagy mechanism. The amino acid sequence of the chimeric molecule is shown by SEQ ID NO: 1 or2 or 3 or 4. The invention also discloses a nucleic acid molecule for encoding the chimeric molecule for mediating mitochondrial targeted degradation based on, an expression vector containing the nucleic acid molecule, and applications of the chimeric molecule, the nucleic acid molecule and the expression vector in targeted degradation of mitochondria. According to the chimeric molecule for mediating mitochondrial targeted degradation, through targeted degradation of intracellular mitochondria, it is proved that regulation and control of intracellular organelles at the cellular level are feasible, and reference is provided for targeted degradation of other organelles; the chimeric molecule disclosed realizes degradation of the intracellular mitochondria at a cellular level, and provides adrug research and development thought for treatment of diseases; and particularly, a certain treatment thought can also be provided for neurodegenerative diseases caused by PINK1-Parkin pathway mutation.
Owner:CHONGQING UNIV
Application of iron transporter in treatment of Parkinson's disease
ActiveCN111718939AEnhance breathing functionHigh activityOrganic active ingredientsNervous disorderDiseaseProtein target
The invention relates to the field of gene engineering, in particular to a target protein of Parkinson's disease (PD) and an encoding gene and application thereof, and particularly relates to preparation of a gene targeting drug aiming at the key gene. The target protein finds that a target gene ZIP13 and Transferrin (Tsf) for Parkinson's disease are provided, and the PD condition is remarkably relieved or delayed by over-expressing the ZIP13 or interfering the Tsf through gene silencing. According to the target protein the human PD target protein comprises amino acid sequences represented bySEQ ID No. 5 and SEQ ID No. 6, and the gene comprises nucleotide sequences represented by SEQ ID No. 7 and SEQ ID No. 8. According to the target gene, an RNAi vector carrying a target gene is constructed, and the athletic ability of a PD patient can be improved through gene silencing or gene overexpression, and PD symptoms caused by knockdown of PINK1 is relieved or prevented. The target protein is expected to provide a novel treatment strategy and a key target for treating hereditary PD.
Owner:HEFEI UNIV OF TECH
Human serine/threonine kinase PINK1 mutant protein and application thereof
InactiveCN108866023AImplement diagnosticsAchieve therapeutic effectMicrobiological testing/measurementTransferasesElisa kitMutated protein
The invention relates to a human serine / threonine kinase PINK1 mutant protein and application thereof. A plurality of patients suffering from leukemia and parkinson's disease are used as studying cases, gene detection and analysis on the cases are performed, the human serine / threonine kinase PINK1 mutant protein is determined, a gene chip, a monoclonal antibody and an ELISA kit are prepared according to the human serine / threonine kinase PINK1 mutant protein, a guidance function is provided for gene diagnosis of patients suffering from leukemia and parkinson's disease, and a scientific basis isprovided for diagnosis and treatment of leukemia and parkinson's disease.
Owner:天津市湖滨盘古基因科学发展有限公司
A recessive gene diagnosis chip for Parkinson's disease
ActiveCN103667500BReliable resultsImprove early diagnosis rateNucleotide librariesMicrobiological testing/measurementMedicineGenetic diagnosis
A diagnosis chip of recessive pathogenic genetic genes of a Parkinson disease has 96 mutational site sequences, namely 23 Parkin, 19 PINK1, 6 DJ-1, 14 ATP13A2, 25 PLA2G6 and 9 FBXO7. The chip comprises the following test steps of: fabricating an SUD plate, resuspending the SUD plate, fabricating an ASE plate, adding MEL, performing preliminary work on PCR (Polymerase Chain Reaction), combining PCR products, preparing a pre-chip sample, performing chip hybridization, cleaning and scanning the chip, and reading and analyzing data. The diagnosis chip of the recessive pathogenic genetic genes of the Parkinson disease is low in cost, and can screen the recessive pathogenic genetic genes of the Parkinson disease conveniently and rapidly.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV
Application of ferroportin in the treatment of Parkinson's disease
ActiveCN111718939BEnhance breathing functionHigh activityOrganic active ingredientsNervous disorderDiseaseProtein target
The present invention relates to the field of genetic engineering, in particular, the present invention relates to a target protein of Parkinson's Disease (PD) and its encoding gene and application, and particularly relates to the preparation of gene-targeted drugs for the above-mentioned key genes. The present invention provides the target genes ZIP13 and Transferrin (Tsf) of Parkinson's disease, and significantly alleviates or delays PD by overexpressing ZIP13 or interfering with Tsf by gene silencing. According to the present invention, the target protein of human PD includes the amino acid sequences shown in SEQ ID No. 5 and SEQ ID No. 6, and the gene includes the nucleus as shown in SEQ ID No. 7 and SEQ ID No. 8. nucleotide sequence. According to the target gene of the present invention, constructing an RNAi vector carrying the target gene can be used to improve the exercise ability of PD patients through gene silencing or gene overexpression, and slow down or prevent PD symptoms caused by knockdown of PINK1. This invention is expected to provide new therapeutic strategies and key targets for the treatment of hereditary PD.
Owner:HEFEI UNIV OF TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com